Amgros is a stakeholder with the 5 regions as stakeholders. With a view to providing stakeholders' hospital pharmacies with medicinal products and the resale of individual stakeholders to the Faroe Islands and Greenland, Amgros I/S wishes to conclude framework agreements for the medicinal products listed in Title II.2.4. The framework agreements are non-exclusive. Amgros I/S resells the medicines to the hospital pharmacies at Amgros I/S's purchase price with a supplement. Framework agreements are concluded without purchasing obligation and hospital pharmacies in the regions are not obliged to use Amgros' framework agreements.

The tender number includes the following medicines:

Tender No: 1,

ATC Code: A16AB20,

Generic name: Pegunigalsidase alfa,

Dispensing form: Conc. Liquid.

Strength: 2 mg/ml,

Unit value: 5 mg,

Volume in units: 9 999.

Each tender number shall be considered a stand-alone subcontract and shall be offered independently of the other tender numbers. Thus, a vendor may choose to offer at one, more or all tender numbers, and allocation is made separately for each offer number. Please refer to the tender conditions, including the submission of tenders under the individual tender numbers.

Under the designation “quantity in units” above, an estimated consumption of the drugs is listed under the tender number, but real consumption may differ significantly from there. This will have to be incurred by suppliers. The background to this is that these are medicines for patient care in public hospitals where the needs of the patient need to be addressed. For details, refer to the terms and conditions of the framework agreement.

The one under section. II.2.6 below stated “Estimated” value is equal to the maximum value of the subagreement.